СЛОВО,Abstract:,The,midbrain,periaqueductal,gray,(PAG),is,a,key,structure,involved,in,the,supraspinal,modulation,of,pain.,Previous,studies,have,reported,association,gut,inflammation-triggered,chronic,abdominal,pain,with,structural,and,neuronal,alterations,within,PAG.,"However,",whether,PAG-executed,visceral,nociception,processing,descending,are,altered,pathology,not,known.,We,used,c-Fos,immunohistochemistry,extracellular,microelectrode,recording,urethane-anesthetized,male,Wistar,rats,to,evaluate,colitis-induced,changes,pain-related,properties,PAG,its,outflow,nociceptive,neurons,caudal,ventrolateral,medulla,(CVLM).,Analysis,protein,expression,inflamed,animals,has,shown,diminished,activation,lateral,columns,by,noxious,colorectal,distension,"(CRD),",although,nonstimulated,labeling,these,subdivisions,was,enhanced,compared,that,controls.,Microelectrode,revealed,colitis-elicited,decrease,proportion,CRD-excited,accompanied,an,increase,number,unresponsive,cells,weakened,reactions,stimulation,CRD-inhibited,units.,Colonic,inflammation,also,been,found,cause,shift,effects,electrostimulation,on,CVLM,from,being,mostly,inhibitory,under,normal,conditions,excitatory,colitis.,These,findings,identify,impaired,functioning,ascending,control,may,contribute,injury-associated,hyperalgesia.,data,obtained,can,benefit,better,understanding,mechanisms,pathogenesis,postinflammatory,"pain.
","Background
",HIV-positive,people,who,inject,drugs,(PWID),stigmatized,face,more,challenges,accessing,ART.,natural,course,stigma,role,ART,initiation,this,population,unclear.,examined,1],HIV,over,time,2],substance,use,associated,prospective,cohort,PWID,St.,"Petersburg,","Russia.
","Methods
",165,were,ART-naïve,at,enrollment,andgeneralized,estimating,equations,assess,between,"baseline,",12-,24-month,study,visits.,Logistic,regression,estimated,associations,initiation.,All,models,adjusted,for,"gender,","age,",CD4,"count,",duration,"diagnosis,",recent,(past,30-day),drug,depressive,"symptoms.
","Results
",Participants,characteristics,following:,median,age,34,(Q1;,Q3:,30;,37),years;,30%,female;,28%,count,<350;,44%,use.,During,"period,",31%,initiated,diagnosis,8.5,years,4.68;,13.61).,scores,decreased,yearly,0.57,(95%,CI,"-1.36,",0.22).,More,than,half,(27/47,[57.4%]),participants,eligible,per,local,guidelines,did,initiate,therapy.,Total,(AOR,"0.99,",95%CI,0.94–1.04;,AOR,"1.01,","0.96–1.05,","respectively).
","Conclusion
",In,Russian,"HIV-positive,","PWID,",change,Addressing,alone,unlikely,rates,population.,Reducing,further,existing,"barriers,","e.g.,",promoting,equal,access,value,substance-use,treatment,success,should,complement,stigma-reduction,"approaches.
","Introduction
",Alcohol,prevalent,among,women,hepatitis,C,Virus,(HCV),co-infection,despite,alcohol's,known,harmful,health,Identifying,factors,facilitate,continued,unhealthy,alcohol,critical,developing,effective,reduction,interventions.,This,assessed,situational,motivational,HIV/HCV,co-infected,clinical,care,Guided,model,"use,",we,conducted,30,semi-structured,interviews,living,drinking,barriers,facilitators,abstaining.,Interviews,recorded,analyzed,using,thematic,analysis,"approach.
",Despite,awareness,risks,many,heavy,episodic,"drinking,",particularly,social,situations.,A,motive,coping,negative,emotions,triggered,stressful,"situations,",such,as,work-,family-related,conflicts.,Key,included,family,friends,Women,endorsed,motives,most,motivated,stop,drinking.,Health,concerns,cited,reasons,drinking;,"however,",few,their,doctors,recommended,they,"abstain.
","Conclusions
",Several,"identified,",well,some,opportunities,"prevention,",Russia.,Awareness-raising,training,regarding,adverse,consequences,persons,include,"clinicians,",patients,"relatives.
",COVID-19,pandemic,various,degrees,lockdown,applied,countries,around,world.,It,considered,measures,effect,mental,but,relationship,measure,intensity,thoroughly,studied.,Here,report,larger,COMET-G,pertaining,"question.
",Material,"pandemic,",gathered,online,questionnaire,"55,589",40,(64.85%,females,aged,35.80 ±,13.61;,34.05%,males,34.90±13.29,1.10%,other,31.64±13.15).,Anxiety,measured,"STAI,",depression,CES-D,suicidality,RASS.,Distress,probable,identified,previously,developed,cut-off,algorithm,"respectively.
",Statistical,"Analysis
",calculation,Relative,Risk,"(RR),",Factorial,ANOVA,Multiple,backwards,stepwise,linear,"analysis
",Approximately,two-thirds,currently,significant,restrictions,due,lockdown.,For,both,risk,develop,correlated,significantly,each,every,level,increasing,degree,(RR,1.72,1.90,respectively).,combined,psychiatric,history,increased,RR,6.88,overall,severity,"depression,",though,"small.
",current,first,which,reports,almost,health.,Our,"findings,",support,previous,suggestions,concerning,need,proactive,targeted,intervention,protect,specifically,vulnerable,"groups
",CE,method,CuSO4,2-hydroxypropyl-β-cyclodextrin,additives,sodium,acetate,background,electrolyte,pH 4.3,simultaneous,determination,amino,acids,lactic,acid,adapted,comparative,metabolism,"""healthy""",non-alcoholic,fatty,liver,disease,HepG2.,vitro,exposure,HepG2,oleate,palmitate,simulate,excessive,flow,into,hepatocytes.,proven,be,consistent,"pathophysiology,",since,intracellular,triglyceride,cytokine,interleukin,8,levels,"increased,",while,viability,decreased.,order,check,"pathology,",proposed,sample,preparation,culture,medium,characterized,evaluating,dynamic,"range,",repeatability,intermediate,precision,peak,areas,migration,"times,",accuracy,(recovery,rate,trueness,reference,"method),",detection,limits,quantitation,limits.,proved,"sensitive,",reliable,highly,accurate,acid.,concentrations,healthy,"Arg,","Ala,","Glu,",Gln,comparison,"control.
",Myeloperoxidase,"(MPO),",oxidant-producing,enzyme,"neutrophils,",prime,platelet,activity,immunothrombosis.,Native,MPO,"homodimer,",consisting,two,identical,protomers,(monomer),connected,single,disulfide,bond.,But,inflammatory,"foci,",form,monomer,dimer.,Beside,complexes,molecules,modified,"oxidants,",ultimately,affect,physicochemical,functions.,forms,complex,ceruloplasmin,"(CP),",physiological,inhibitor,"MPO,",activity.,Monomeric,(hemi-MPO),treating,dimeric,reductive,alkylation.,HOCl,molar,ratio,1:100,(MPO-HOCl).,Using,surface-enhanced,Raman,scattering,(SERS),spectroscopy,showed,peaks,about,510,526 cm−1,corresponded,bond,recognizable,SERS-spectra,absent,spectrum,hemi-MPO,less,intense,spectra,"MPO-HOCl,",indicates,partial,decomposition,cleavage,modification.,lesser,extent,bound,platelets,agonist-induced,aggregation,platelet-neutrophil,aggregate,formation.,CP,bind,no,"Thus,",modification,"HOCl,",presence,monomeric,reduces,function,consequently,decreases,thrombosis,"foci.
",Moscow,"1950′s,",physicist,M.,Bongard,silent,substitution,establish,dimensions,human,or,animal,colour,vision,derive,colour-matching,functions,either,whole,organisms,individual,channels.,"1956,",he,his,colleague,S.,Smirnov,extra-foveal,tetrachromatic,when,tested,silent-substitution,called,‘replacement,colorimetry’.,steady,"state,",trichromatic,matches,possible,"regions,",transients,visible,one,match,replaced,another.,"If,",made,four,"primaries,",then,possible;,–,unlike,ones,stable,light,state,chromatic,adaptation.,believed,fourth,receptor,had,spectral,sensitivity,"rods,",working,long,before,discovery,intrinsically,photosensitive,retinal,ganglion,cells.,On,fiftieth,anniversary,Bongard’s,grievous,"death,",provide,translation,Smirnov’s,paper,tetrachromacy,vision.,"commentary,",give,work,details,apparatus,procedure.,briefly,discuss,related,research,reception,West,claims.,suggest,analogy,parafovea,‘weak,tetrachromacy’,heterozygotes,anomalous,"vision,",whose,"adaptation.
",Bipolar,(BPD),deficits,"cognition,",there,still,controversies,medications,cognitive,performance.,"Here,",investigated,cognition,terms,executive,"functions,","memory,",attention,first-episode,medication-naive,BPD,taking,olanzapine.,Forty-one,"controls,",unmedicated,drug-naive,"patients,",took,only,olanzapine,recruited,study.,Cognitive,performance,Flanker,"test,",Stroop,Corsi-block,test.,Bayesian,multivariate,run,considering,maximum,robustness,avoid,bias,predict,outcomes.,results,performed,worse,controls,group,tasks.,"Additionally,",patients.,acute,predicted,dosage,serum,"(i.e.,",large,effects).,potential,pro-cognitive,carefully,interpreted,variables.,expect,our,will,"area,",goal,helping,"researchers,","population.
","Summary
",Predicted,increases,suicide,generally,observed,early,months,pandemic.,picture,changing,patterns,might,vary,across,demographic,groups.,aimed,"timely,",granular,pandemic's,impact,suicides,"globally.
",official,public-sector,sources,"countries/areas-within-countries,",searching,websites,academic,literature,contacting,custodians,authors,necessary.,sent,request,22nd,June,2021,stopped,collecting,31st,October,2021.,interrupted,series,(ITS),analyses,emergence,total,"sex-,",age-,sex-by-age,country/area-within-country.,expected,numbers,nine,10-15,meta-regression,explore,"variation.
","Findings
",sourced,33,(24,"high-income,",six,"upper-middle-income,",three,lower-middle-income;,25,whole-country,"data,",12,"area(s)-within-the-country,",both).,There,evidence,greater-than-expected,majority,countries/areas-within-countries,any,analysis;,"commonly,",lower-than-expected,numbers.,Certain,"sex,",groups,stood,out,potentially,"concerning,",countries/areas-within-countries.,"meta-regression,",different,explained,countries’,mortality,"rate,",stringency,public,"response,",economic,"level,",national,prevention,strategy.,Nor,income,high-income,upper-middle-income,"countries,",ITS,lower-middle-income,fared,"well.
","Interpretation
",Although,where,certain,sex-,age-based,"greater-than-expected,",minority.,Any,upward,movement,place,remain,alert,respond,"continue.
","Funding
","None.
","Abstract
",ALK-positive,histiocytosis,rare,subtype,histiocytic,neoplasm,described,2008,3,infants,multisystemic,involving,hematopoietic,system.,entity,subsequently,documented,case,occupy,wider,clinicopathologic,recurrent,KIF5B-ALK,fusions.,full,molecular,"remain,",poorly,characterized.,describe,largest,"date,",detailed,39,"cases,",including,37,cases,confirmed,ALK,rearrangements.,comprised,distinct,phenotypic,groups:,"involvement,",originally,(Group,1A:,"6/39),",1B:,"10/39),",single-system,2:,23/39).,Nineteen,entire,(49%),neurologic,involvement,(7,Groups,1B,"2,",Histology,classic,xanthogranuloma,features,one-third,whereas,displayed,densely,"cellular,",monomorphic,appearance,without,lipidized,histiocytes,sometimes,spindled,epithelioid,morphology.,Neoplastic,positive,macrophage,markers,often,conferred,strong,phosphorylated,signal-regulated,"kinase,",confirming,MAPK,pathway,activation.,fusions,detected,27,"CLTC-ALK,","TPM3-ALK,","TFG-ALK,","EML4-ALK,",DCTN1-ALK,cases.,Robust,durable,responses,11/11,treated,"inhibition,",10,involvement.,presents,landscape,provides,guidance,management,emerging,"entity.
",Essential,tremor,(ET),common,disorders.,heterogeneity,ET,studied,"years,",practically,comprehensive,dedicated,assessment,biochemical,electrophysiological,parameters,motor,non-motor,disorders,present,account,"heterogeneity.
","Objectives
",objective,differentiate,subgroups,essential,cluster,"clinical,","parameters.
",enrolled,90,ET.,Clustering,perform,scales,"FTMS,","ADL,","MoCA,","Beka,",surface,electromyographic,"IL-1β,","IL-6,","IL-8,","IL-10,","TNFα,",uric,"acid,","ceruloplasmin,","MDA.
",Based,"manifestations,",psychoemotional,adaptive,aspects,"pathogenesis,",relatively,homogeneous,clusters,"identified.
",Revealing,allows,expand,"disease.
",Implantation,stimulating,electrodes,basement,vertebral,spinous,process,quickly,stably,fixed,relative,spinal,cord.,"approach,",selectivity,rat,muscle,during,transvertebral,(TS).,"work,",TS,induce,forward,stepping,cat's,hindlimbs,epidural,"(ES).
",Materials,electrode,placed,VL3–VL6,vertebrae,five,decerebrated,cats.,ES,same,cats,L5–L7,segments.,Kinematic,addition,musculus,(m.),iliopsoas,"(IP),",m.,tibialis,anterior,"(TA),",gastrocnemius,lateralis,(GL),"hindlimbs.
",With,VL3–VL4,"TS,",all,capable,bipedal,"stepping,",VL5,VL6,led,5,1,"animals,",respectively.,Well-coordinated,high,intra-,interlimb,coordination.,TS-induced,similar,those,ES.,VL3,vertebra,causes,frequency,lock,integer,multiple,frequency.,Similarly,"model,",TS-evoked,site,specific.,They,minimal,maximal,VL4–VL5,(IP),VL5–VL6,"(TA,","GL).
",hypotheses,location,central,pattern,generators,upper,lumbar,approach,placement,surgically,easier,useful,studying,site-specific,neuromodulation,sensorimotor,networks,investigating,new,strategies,locomotor,recovery,"models.
",Changes,sex,hormones,menopause,detrimental,woman's,sexual,mood,challenge,"gynecology.
","Aim
",To,review,published,peri-,postmenopausal,"women.
",based,methodological,framework,scoping,reviews.,searched,electronic,databases,Medline,"(PubMed),","Scopus,","Embase,",Web,Science,(WoS).,Publications,menopausal,review.,search,subject,limitation,"method.
","Outcomes
",main,outcome,dysfunction,"disorders.
",106,records.,After,full-text,screening,19,1986,2020,methodologies;,studies16,cross-sectional.,Investigations,addressed,symptoms,domains,close,Clinical,"implications
","practice,",it,would,appropriate,screen,least,disorder,dysfunction.,If,woman,suffers,"either,",necessary,Strengths,&,"Limitations
",reproductive,age.,importance,"subject,",inclusion,rather,small.,Further,investigation,topic,clearly,"warranted.
",While,appears,"bidirectional,",future,investigate,specific,could,lead,(or,vice,versa).,Future,address,dysfunctions,attitudes,"partners,","BMI,","support,","sleep,",multiparity.,Azam,"Rahmani,",Elahe,"Afsharnia,",Julia,"Fedotova,",Shirin,"Shahbazi,",Arezoo,"Fallahi,",Leila,"Allahqoli,",Reza,"GhaneipoklGheshlagh,",Sarah,"Abboud,",Ibrahim,Alkatout.,Sexual,Function,Mood,Disorders,Among,Menopausal,Women:,Systematic,Scoping,Review.,J,Sex,Med,"2022;19:1098–1115.
",Allogeneic,stem,cell,transplantation,(HSCT),curative,affected,Wiskott-Aldrich,syndrome,(WAS).,Reported,HSCT,outcomes,improved,respect,"survival,",older,alternative,donors,predicting,poorer,outcome.,197,undergoing,transplant,European,Society,Blood,Marrow,Transplantation,centers,2006,2017,received,conditioning,Inborn,Errors,Working,Party,(IEWP):,busulfan,(n,=,103),treosulfan,94),fludarabine,±,thiotepa.,follow-up,post-HSCT,44.9,"months,",176,"alive,",resulting,3-year,survival,88.7%,graft-versus-host,(GVHD)-free,(events,graft,"failure,",severe,GVHD),81.7%.,Overall,GVHD-free,regimen,(busulfan-,vs,"treosulfan-based),",donor,type,(matched,sibling,donor/matched,matched,unrelated,donor/mismatched,mismatched,"donor),",period,(2006-2013,2014-2017).,Patients,<5,survival.,cumulative,incidences,grade,III,IV,GVHD,extensive/moderate/severe,6.6%,"2.1%,",receiving,treosulfan-based,higher,incidence,failure,mixed,chimerism,frequently,underwent,secondary,procedures,(second,"HSCT,",unconditioned,"boost,",lymphocyte,"infusion,",splenectomy).,"summary,",WAS,regimens,IEWP,excellent,low,"GVHD,",regardless,"source,",≥5,remains,factor,"survival.
",tetrahydrobiopterin,(BH4),reduced,schizophrenia.,BH4,deficiency,schizophrenia,precisely.,Objective:,range,evaluation,loss,development,symptoms.,Methods:,93,60,volunteers,randomly,selected,evaluated,examination,"BH4,","folate,",cobalamin,"(B12),","homocysteine,",C-reactive,"(CRP),",glutathione,(GSH),blood,serum.Patients,standardized,psychopathological,examination.,Results:,folate,lower,(p = 0.001,"p = 0.054,","respectively),",homocysteine,(p = 0.012),group.,directly,moderately,(ρ = 0.43;,p = 0.0029),B12,p = 0.0020),inversely,(ρ = −0.54;,p = 0.00015),Cluster,biotype,"B12,",hyperhomocysteinemia.,CRP,GSH,"confirmed.
",noninvasive,tools,help,understand,states,caused,"medications,",symptom,"severity,",low-level,visual,contrast,"(CSF),","reliable,","robust,",widely,approach.,purpose,(1),impairments,(SCZ),bipolar,(2),variables,diseases.,Fifty-six,(HCs;,mean,age = 31.04,"years),",42,(mean,age = 32.84,years),"lithium,",SCZ,age = 32.80,CSF,differed,Both,exhibited,discrimination,"low,","mid-,",spatial,frequencies,HCs.,No,differences,exception,"variables,",mediation,analyses.,aid,investigations,state-,trait-like,patient,populations.,underscores,remediation,"interventions.
",aim,article,retrospective,PDT,effectiveness,early-stage,cervical,cancer,HPV,elimination,via,"PDT
","methods
",28,"retrospectively,",cancer.,session,multi-course,depended,reaction,response,therapy,after,session.,months.,Treatments,2015,2020.,Relapse-free,probability,Kaplan,Meier,estimator,elimiantion,"examined..
",82%,three-month,(R2 = 0.71).,90%,"0,8",(CI95%:,"0,53–1)",mild,(35.7%),(28.6%),leucocyte,"months.
",demonstrates,CC,five-year,relapse-free,PDT.,completing,multi-treatment,protocol,invasive,achieve,Background:,ALL,intensive,non-interruptive,RALL-2009,fulfilled,auto-hematopoietic,T-cell,reliably,improve,free,(DFS).,non-randomized,"trial,",selection,limited,auto-HSCT,chemotherapy,(ChT),only.,Aim:,appreciate,T-ALL,adult,RALL-2006,protocol.,Patients:,RALL-2016,achieved,complete,(CR),brought,randomization,informed,consent,ChT,267,Ph-negative,Dec,2016,until,Apr,2022.,111,"T-ALL,",74%,"male,",31.,5y,(OS),DFS,68%,"66%,",precursor,(ETP)-ALL,poor,"prognosis,",relapse,(PR),(52%,1st,year,CR).,87,(pts),randomized:,43,pts,"ChT,",44,auto-HSCT.,refused,"group,",4,auto-HSCT;,censored,refuse.,deaths,CR,"arms,",went,allo-HSCT,mixed-lineage,leukemia,(MLL),"leukemia,",Niimegem,MRD,persistence).,done.,transplanted,patients:,7,conditioned,"iomustine,","etoposide,","cytarabine,",melphalan,(CEAM),Maintenance,start,1.5,HSCT.,Transplant-related,5%.,Landmark,"post-HSCT,",didn't,detect,PR,(67%,"78%,",25%,22%,ChT).,Auto-HSCT,does,induction.,persistence,induction,(MRD-:,86%,81%,MRD+:,67%,"40%,",respectively,auto-HSCT).,Conclusions:,auto-HCST,long-term,result,ALL.,ETP-phenotype,independent,prognostic,factor.,Addition,late,high-dose,consolidation,"therapy.
",Medieval,yoga,texts,claim,special,exercise,muscles,"wall,","agnisara,",improves,digestive,function.,Main,demonstrate,through,superior,mesenteric,artery,(if,any),"agnisara.
",Ultrasound,volumetric,indicators,(SMA),performing,agnisara,100,times,carried,sexes,(8,them,"women).
",diameter,"SMA,",systolic,diastolic,"velocities,","found,",contrasts,established,splanchnic,humans,physical,"activity.
",Properly,"region,",registered,adequate,supply,gastrointestinal,tract,successful,"function.
",Adequate,maternal,thyroid,important,uncomplicated,pregnancy.,observational,hypertensive,"pregnancy,",methods,definitions,abnormalities,tests,"heterogeneous,",conflicting.,examine,gestational,hypertension,"pre-eclampsia.
",systematic,meta-analysis,individual-participant,MEDLINE,"(Ovid),",Cochrane,Database,Reviews,date,inception,"27,","2019,",thyroid-stimulating,hormone,"(TSH),",thyroxine,"(FT4),",peroxidase,(TPO),"antibodies,",individually,"combination,","hypertension,","pre-eclampsia,",both.,issued,open,invitations,participate,Consortium,Thyroid,Pregnancy,share,data.,excluded,pre-existing,multifetal,primary,pre-eclampsia.,Individual-participant,analysed,logistic,mixed-effects,adjusting,"smoking,","parity,","ethnicity,",sampling.,"PROSPERO,","CRD42019128585.
",1539,"studies,",cohorts,met,criteria,agreed,participate.,46 528,pregnant,"women,",whom,39 826,(85·6%),sufficient,(TSH,FT4,TPO,antibody,status),classified,according,status.,Of,1275,(3·2%),subclinical,"hypothyroidism,",933,(2·3%),isolated,"hypothyroxinaemia,",619,(1·6%),"hyperthyroidism,",337,(0·8%),overt,hyperthyroidism.,Compared,"euthyroidism,",hypothyroidism,pre-eclampsia,(2·1%,3·6%;,OR,1·53,[95%,1·09–2·15]).,Subclinical,positivity,continuous,"analyses,",TSH,concentration,(p=0·0001).,"measured.
",pregnancy,U-shaped,quantify,test,"abnormalities,",adding,body,fetal,implications,defining,optimal,target,levothyroxine,needs,interventional,"studies.
",Arkansas,Biosciences,Institute,Netherlands,Organization,Scientific,"Research.
","ABSTRACT
",Cyclosporine,(CSA),methotrexate,(MTX),standard,(GVHD),prophylaxis,(MSD),allogeneic,(allo-HCT).,"Recently,",post-transplantation,cyclophosphamide,(PTCy),prevention.,registry-based,"study,",118,PTCy,1202,CSA/MTX,MSD,allo-HCT,myelogenous,leukemia.,matched-pair,"analysis,",2,(41.1%,versus,21.3%;,P = .039).,day,+180,II-IV,2-year,comparable,arms,(25.2%,25.4%,[P = .90],42.6%,"[P = .84],","Similarly,",leukemia-free,(LFS;,54.4%,74.32%;,"P = .052),",(OS;,70.6%,79.7%;,"P = .15),",(GRFS;,38.1%,52.5%;,P = .49),statistically,arms.,show,"feasible,","GRFS,","LFS,",OS,seen,conventional,MSD.,©,American,Cellular,Therapy.,Published,Elsevier,"Inc.
",Impaired,"colitis,
",Stigma,lifetime,illicit,"Saint-Petersburg,",Russia–A,"analysis,
",Situational,"co-infection,
",self-identified,gender,"anxiety,",pandemic:,Data,international,"study.,
",Cu2+,ions,composition,cellular,"disease,
",Structure-biological,relationships,myeloperoxidase,"activation,
","vision,
",Serum,"disorder,
",Suicide,9-15,trends:,An,"countries,
",histiocytosis:,highlighting,"inhibition,
",Exploratory,"study,
",Forward,Stepping,Evoked,Transvertebral,Stimulation,Decerebrate,"Cat,
","Review,
",Hematopoietic,syndrome:,EBMT,Tetrahydrobiopterin,schizophrenia:,Biochemical,"aspects,
",Correlates,Photodynamic,"treatment,
",ALL-056,Late,Intensification,Autologous,Non-Myeloablative,CEAM,Conditioning,Can't,Improve,Results,Therapy,Adults,T-Cell,Acute,Lymphoblastic,Leukemia,(ALL),Treated,Non-Intensive,Protocol:,Multicentral,Prospective,Randomized,RALL,"Study,
",Yogic,"artery,
",Association,pre-eclampsia:,"meta-analysis,
",Graft-versus-Host,Disease,Prophylaxis,Post-Transplantation,Cyclophosphamide,Methotrexate,Matched,Sibling,Donor,"Transplantation,
"
ВСТРЕТИЛОСЬ_РАЗ_в_2022,21,35,2,2,2,1,29,67,2,1,2,147,217,2,2,229,1,1,9,13,7,8,3,1,7,3,1,104,2,249,3,1,1,1,3,4,1,6,2,4,3,13,2,1,21,1,23,6,3,1,2,1,2,1,1,1,2,98,2,1,7,2,2,7,6,1,1,3,1,4,1,1,1,2,2,1,2,7,5,1,2,1,1,37,1,1,1,1,2,1,1,6,1,47,2,10,24,1,1,3,1,2,1,2,1,12,3,4,1,5,1,2,4,1,1,1,1,7,8,4,2,1,9,1,32,1,21,1,1,1,3,2,2,1,1,5,4,2,1,1,1,2,4,3,1,1,20,4,6,1,3,2,4,2,1,1,6,3,2,13,1,1,1,1,1,7,1,1,1,1,2,11,4,13,7,15,2,1,1,1,12,4,8,1,3,14,15,4,5,2,2,2,2,9,1,72,2,10,1,1,1,1,2,17,1,1,1,15,1,1,4,2,2,2,2,2,1,53,1,2,2,1,1,1,2,1,1,3,1,1,8,1,2,1,5,6,2,2,2,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,4,1,1,3,1,1,1,1,2,1,1,1,6,1,1,1,3,2,1,1,1,3,1,1,1,1,1,2,1,1,1,1,1,3,18,4,1,1,2,1,1,1,2,2,1,5,2,1,1,2,1,1,1,1,8,1,5,1,1,1,2,1,1,10,14,2,2,2,1,3,1,1,1,1,8,1,6,1,1,4,9,1,1,2,2,1,7,4,4,5,3,1,17,2,1,7,2,15,1,1,1,1,2,4,2,2,1,1,2,4,5,1,10,1,2,1,2,2,1,1,1,1,2,2,8,1,2,2,1,1,1,1,4,19,1,1,1,1,8,4,1,1,1,1,2,1,2,1,1,1,1,1,1,4,1,8,1,3,4,1,5,1,1,4,6,1,1,1,1,1,1,3,2,1,2,1,39,1,6,3,4,2,6,2,4,1,1,4,1,2,8,6,9,6,1,1,1,1,2,2,1,2,1,1,2,1,1,1,1,1,2,1,2,4,1,1,1,2,1,1,7,1,1,2,1,4,1,2,1,1,1,6,2,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,4,1,1,1,2,3,1,1,1,2,11,10,1,3,3,2,1,3,1,2,1,1,1,3,2,1,2,1,1,1,9,3,1,1,1,1,7,8,2,2,1,5,1,3,1,2,2,3,1,1,1,1,2,1,1,3,4,1,2,2,1,1,2,1,1,1,1,5,6,3,2,1,1,2,1,2,3,4,12,1,1,1,1,1,1,1,1,7,3,1,1,15,2,1,1,1,1,1,1,1,12,1,1,1,1,1,1,1,2,1,1,3,3,2,1,1,1,1,1,1,2,1,1,1,1,1,3,1,1,1,1,1,2,1,1,1,1,1,1,1,4,7,1,1,1,1,2,1,1,1,1,1,1,1,5,4,1,1,14,1,1,3,1,1,1,1,2,3,1,1,2,1,3,1,1,1,1,1,3,1,1,2,1,1,1,3,1,1,1,1,2,2,1,1,1,4,1,1,3,1,1,1,1,2,1,1,1,1,1,3,1,4,1,1,1,2,1,1,1,4,2,3,1,2,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,3,1,1,1,2,1,1,13,1,1,1,1,1,1,1,3,5,2,2,1,1,2,20,2,2,2,1,1,2,2,1,1,2,1,1,1,1,1,1,3,4,1,2,1,1,2,1,1,1,2,3,3,2,1,1,1,5,2,1,1,1,2,2,1,1,1,3,1,1,2,1,1,2,1,1,1,1,14,1,2,1,1,2,3,1,1,1,1,1,1,1,1,1,1,1,2,3,1,2,1,3,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,5,1,1,2,5,1,2,3,1,2,1,1,1,1,1,2,9,3,1,1,2,3,1,5,4,5,7,2,3,1,4,1,2,1,1,1,1,1,1,2,1,1,1,1,1,1,7,6,1,3,4,1,1,3,5,1,1,3,1,1,1,3,1,1,1,2,1,2,3,1,1,1,1,1,2,1,3,5,1,7,2,6,1,2,1,2,1,1,2,2,2,2,1,1,3,1,5,1,1,1,2,1,1,1,1,3,1,1,3,1,1,1,1,1,2,1,1,1,1,1,2,3,1,2,1,4,1,1,2,1,1,6,1,1,2,1,1,2,1,3,1,1,1,1,3,1,2,1,4,3,1,1,2,3,1,3,3,3,1,1,1,1,1,1,4,1,2,2,2,1,1,3,2,2,2,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,1,1,2,2,2,1,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,2,5,4,1,1,2,1,2,1,2,2,3,1,4,1,1,1,2,1,1,1,5,1,2,1,2,2,1,1,1,1,1,1,2,2,3,2,1,3,1,3,1,2,1,1,2,1,1,3,1,1,1,1,1,1,1,1,1,1,3,2,1,1,1,1,1,1,1,2,1,3,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,2,3,1,1,1,1,1,1,2,1,1,3,1,4,1,1,1,1,1,1,1,1,1,1,1,4,1,1,2,2,3,2,1,1,1,1,1,6,3,4,2,1,9,1,1,1,3,2,1,1,3,1,2,1,1,1,1,1,2,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,2,1,1,1,1,1,1,1,1,3,1,1,1,2,3,9,1,1,1,7,1,3,4,1,1,1,1,1,2,1,1,1,2,1,1,1,1,1,1,2,2,1,1,1,1,1,2,1,2,1,1,1,1,1,3,1,1,3,1,1,1,1,1,2,2,2,1,3,1,5,1,1,1,1,4,1,2,2,1,1,1,1,1,2,2,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,11,10,1,1,1,2,7,3,1,1,2,4,1,1,1,1,2,1,1,1,1,2,2,1,1,1,1,3,1,3,1,1,1,1,2,1,7,1,1,1,3,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,2,1,1,1,1,1,1,2,2,1,3,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,2,2,3,2,2,3,2,1,1,1,1,1,1,5,6,4,2,1,2,2,2,1,1,6,5,1,1,1,1,1,1,1,1,1,1,2,2,1,2,1,1,2,1,1,1,1,4,2,2,2,2,1,1,2,2,1,1,1,1,1,1,1,1,1,1,1,1,2,1,10,1,2,1,1,2,1,2,1,1,1,2,2,1,12,1,7,1,1,2,1,2,2,1,1,1,3,1,1,5,1,1,1,3,2,1,1,6,1,1,1,1,1,9,2,1,1,1,1,4,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,1,2,1,6,4,6,1,1,1,2,1,1,1,1,1,3,2,1,1,2,2,2,2,1,1,1,1,1,1,1,9,1,1,1,1,2,2,3,1,1,1,2,1,1,1,2,2,1,1,1,1,1,1,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,6,1,1,1,1,1,3,1,1,2,1,3,1,3,1,1,1,1,1,1,1,2,1,2,1,1,1,1,1,1,1,1,1,1,2,1,1,1,2,1,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,7,1,4,5,4,4,3,1,1,1,1,1,1,1,2,1,1,4,2,13,1,3,1,1,1,2,4,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,3,1,1,1,4,1,1,1,3,1,1,1,2,1,3,2,4,2,1,1,1,1,1,7,1,1,2,1,1,6,2,1,1,1,1,1,1,1,1,1,1,1,4,1,1,2,1,1,1,1,1,1,1,1,1,1,1,4,1,1,1,1,3,1,3,1,1,1,1,1,1,1,1,1,2,1,1,2,2,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,4,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,2,1,1,1,1,1,1,1,2,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,3,1,1,1,1,2,2,1,1,1,4,4,3,1,1,1,1,1,1,1,2,4,2,2,1,1,1,1,1,1,2,1,1,1,1,1,1,2,1,1,1,1,1,2,1,1,1,1,1,1,1,5,11,1,1,2,1,1,3,1,1,2,2,1,1,1,7,5,1,2,1,3,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,4,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,2,1,1,1,1,1,2,2,2,1,1,1,1,1,1,1,4,1,1,1,2,2,1,1,2,1,1,1,1,2,2,2,3,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,5,1,4,1,2,1,1,1,1,2,1,7,1,1,1,1,1,2,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1
